Brian Horner, MD
Internal Medicine · Salt Lake City, UTNPI 1336465939
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Madrigal Pharmaceuticals at 25.3% of the total. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 428 payments — averaging $48.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$5K
- Mirum Pharmaceuticals, Inc.$3K
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Pfizer$2K
- Johnson & Johnson$1K
- plus $5K from 32 others
What the payments were for
- Consulting fees$2,97514%
- Speaking & faculty fees$4,84823%
- Travel & lodging$1,5197%
- Food & beverage$11,00353%
- Education$3412%
- Gifts$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$4,588
- VELSIPITY$1,300
- Skyrizi$390
- GENERAL - BILIARY DEVICES$361
- Entyvio$236
- ACQUIRE$122
- Rinvoq$108
- Resolution 360 Clip$103
How this compares
$20,730 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 13 | $578,855 |
| XifaxanRifaximin | 13 | $32,363 |
| LinzessLinaclotide | 12 | $8,712 |
| Budesonide DrBudesonide | 18 | $4,968 |
| Mesalamine | 20 | $4,133 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 27 | $3,318 |
| Mesalamine ErMesalamine | 12 | $3,093 |
| Pantoprazole Sodium | 114 | $1,211 |
| Omeprazole | 59 | $1,177 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $416 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 29 | $411 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 18 | $351 |
| Dicyclomine Hcl | 20 | $238 |
| Amitriptyline Hcl | 11 | $135 |
| Ondansetron Hcl | 34 | $107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $2,207 | $578,85513 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $150 | $32,36313 claims |
| AbbVieLinzess | $2,680 | $8,71212 claims |
| Braintree Laboratories, Inc.Suflave | $134 | $3,31827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Salt Lake City
- Willard DereSalt Lake City$4.7M
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Gerald GleichSalt Lake City$22K
- Rachel HessSalt Lake City$18K
- Linda VennerSalt Lake City$8K
- David KuoSalt Lake City$8K
- Evan DaughertySalt Lake City$6K
- Margaret LuntSalt Lake City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.